Well-tolerated new drugs to fight drug-resistant CMV in transplant patients
Official title: Development of well tolerated novel Inhibitors of drug resistant CMV
Funded at Microbiotix, INC · NIH-11387896 · Data updated 2026-11-12
A new class of CMV drugs that are easier to tolerate is being developed to prevent or treat CMV infections in people who have had solid organ or bone marrow transplants.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Microbiotix, INC NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project start | August 8, 2025 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $289,318 |
| NIH project number | 5R43AI188690-02 |
| Project ID | NIH-11387896 on NIH RePORTER |
Who could benefit from this research
✓Could help
Transplant recipients (solid organ or bone marrow) who are at risk for or have CMV infection may benefit from this research as it progresses.
✕Less likely to help
People without CMV risk or those not undergoing transplantation may not directly benefit.
What this research studies
This project aims to create a novel non-nucleoside drug (MBXC-4302) that blocks CMV early in its replication cycle. It focuses on drug-resistant CMV strains to improve outcomes for transplant recipients who currently face high risk of CMV disease and related complications. The work uses a human CMV reporter system to identify promising compounds and tests their safety and drug-like properties in the lab. If successful, the therapy could become an option to prevent CMV infection or treat it with fewer side effects than existing medicines.
Why it matters
Potential benefit: If successful, patients undergoing transplants may have a safer, better-tolerated option to prevent or treat CMV infections.
How similar studies have gone: Early-stage CMV drug development has shown promise in lab settings, but this represents a novel class with a focus on drug tolerance and resistant strains.
Where this research is happening
-
Microbiotix, INC
Worcester, United States Active
Researchers
- Principal investigator: Bowlin, Terry L. — Microbiotix, INC
- Study coordinator: Bowlin, Terry L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.